N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that an updated investor presentation incorporating the Company’s acquisition of a 71% interest in Nanogencis Limited is now available on the N4 Pharma website.
N4 Pharma updated investor presentation
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
